SEBI Approves Molbio Diagnostics IPO Proposal

SEBI Approves Molbio Diagnostics IPO Proposal 

SEBI approval on December 1, 2025 allows Molbio Diagnostics to move forward with its ₹200.00 crore IPO and OFS of upto 1.26 crore shares. 

SEBI granted approval for Molbio Diagnostics’ Initial Public Offer (IPO) on December 1, 2025, enabling the company to proceed with listing preparations. The approval is valid for 12 months, giving flexibility to launch the issue based on market conditions and other regulatory clearances.  

The IPO will include a fresh issue of ₹200.00 crores and an offer for sale of upto 1.26 crore equity shares. Details such as price band, lot size, and subscription dates will be announced later. 

SEBI Approval and IPO Structure 

The Securities and Exchange Board of India (SEBI) has cleared Molbio Diagnostics’ IPO proposal, marking a key regulatory milestone. The issue will be a Book Build Issue comprising two components: a fresh issue of ₹200.00 crores and an offer for sale of upto 1.26 crore shares by existing shareholders.  

The equity shares will be listed on NSE and BSE after completion of the process. Kotak Mahindra Capital Co. Ltd. is the book running lead manager, while Kfin Technologies Ltd. will act as the registrar. 

Company Profile and Core Offerings 

Molbio Diagnostics, incorporated in 2000, specialises in point-of-care diagnostics aimed at delivering rapid and cost-effective healthcare solutions. Its flagship product, the Truenat platform, is a portable PCR system that enables decentralised diagnosis within an hour.  

As of March 31, 2025, Truenat is patented in over 100 countries and supports molecular testing for 30 diseases through 42 assays. The Truenat TB test is one of only two WHO-endorsed rapid molecular tests for initial TB diagnosis and rifampicin resistance detection. 

Manufacturing Footprint and Global Reach 

The company operates five manufacturing facilities in India, including two in Goa, one in Visakhapatnam, and two in Bengaluru. These facilities produce diagnostic devices, test kits, and radiology products such as ultraportable and mobile X-ray systems.  

Molbio Diagnostics has a presence in over 80 countries through 33 international distributors and has sold more than 10,000 devices as of March 31, 2025. Products are supplied directly and via distributors to public health programmes, diagnostic laboratories, and hospitals. 

Next Steps and Market Expectations 

Following SEBI approval, Molbio Diagnostics will finalise IPO timelines, price bands, and lot sizes in consultation with its lead manager. The approval remains valid for 12 months, allowing the company to time the launch based on prevailing market conditions.  

Investors will be able to subscribe once the company announces the official schedule and terms. The listing on NSE and BSE will provide liquidity and broaden investor participation in the healthcare technology segment. 

Read More: India Leads Global IPO Activity in October with 2 of Top 5 Deals. 

Conclusion 

SEBI’s approval on December 1, 2025 enables Molbio Diagnostics to move towards the capital markets through a mix of fresh equity issuance and an offer for sale. The proposed listing on the NSE and BSE, along with the company’s strong product portfolio and global footprint, positions it for the next phase of growth.  

Further details on pricing and subscription timelines are yet to be announced. These will depend on regulatory clearances and prevailing market conditions. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.